Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock Holdings Trimmed by Exome Asset Management LLC

Exome Asset Management LLC decreased its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 49.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,152 shares of the company’s stock after selling 136,748 shares during the quarter. Exome Asset Management LLC owned 0.10% of Centessa Pharmaceuticals worth $2,209,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC grew its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP raised its position in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP bought a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter worth approximately $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the 2nd quarter valued at approximately $99,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $16.57 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock has a market capitalization of $2.18 billion, a P/E ratio of -10.83 and a beta of 1.52. Centessa Pharmaceuticals plc has a 12-month low of $6.65 and a 12-month high of $18.97. The firm’s 50 day moving average is $16.50 and its 200-day moving average is $13.27.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CNTA shares. B. Riley assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price on the stock. BMO Capital Markets boosted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Guggenheim lifted their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Jefferies Financial Group lifted their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $25.83.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.53, for a total value of $909,150.00. Following the completion of the sale, the chief executive officer now directly owns 721,924 shares of the company’s stock, valued at $11,933,403.72. This represents a 7.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 16,619 shares of the stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total transaction of $260,752.11. Following the completion of the sale, the insider now owns 206,750 shares of the company’s stock, valued at approximately $3,243,907.50. The trade was a 7.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 262,624 shares of company stock valued at $4,497,698 in the last three months. 11.59% of the stock is currently owned by company insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.